Skip to main content
Publications
Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, Skoldunger A, Karlsson A, Anderson R, Belger M, Bruck C, Espinosa R, Hlavka J, Jutlowitz E, Lin P-J, Lopez Mendez M, Mar J, Shewmaker P, Spackman E, Tafozzoli A, Tysinger B, Jonsson L. Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge. Alzheimers Dement. 2023 May;19(5):1800-20. doi: 10.1002/alz.12811
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Ferrer P, Sabate M, Ballarin E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibanez L. Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010. Springerplus. 2015 Oct 15;4:612. doi: 10.1186/s40064